BSE filing, NSE: YESBANK. Summary written from the filing by ALFA Finder's alert engine.
YES Bank Ltd: key numbers
- Share price
- ₹15.22
- Market cap
- ₹47,776 Cr
- Revenue (annual)
- ₹30,208 Cr
- Net profit (annual)
- ₹3,512 Cr
- P/E (TTM)
- 11.4×Sector 19.1×
- Promoter holding
- 0.00%+0.00% QoQ
- FII holding
- 47.83%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from YES Bank Ltd
All →YES Bank Debt & Borrowing
Yes Bank is assessing a Supreme Court judgment on its AT-1 bonds. The coupon decision for the 18 October 2026 payment remains pending.
YES Bank Employee Stock Options
Yes Bank allotted 7,04,418 equity shares on exercise of employee stock options under its ESOS 2020 and RSU Plan 2024. The bank realised about ₹63.27 lakh and its paid-up capital rose accordingly.
YES Bank Credit Rating
Yes Bank announced that Moody's Investors Service has reaffirmed its long-term foreign currency issuer rating, deposit ratings, and baseline credit assessment at their existing levels.
YES Bank Results Correction
Yes Bank issued a corrigendum correcting the description of the Auditor's report on its financial results for the quarter ended September 30, 2026.
YES Bank Earnings Call Transcript: Key Takeaways
Yes Bank reported strong profit growth but faces a significant capital overhang following a Supreme Court judgment on AT1 bonds.
YES Bank Investor Presentation: Key Takeaways
Yes Bank reported strong Q2FY27 results with Net Profit up 65% YoY to INR 1,080 Crs. Performance was driven by healthy growth in NII and core fee income alongside improved asset quality.
Other regulatory approval announcements
All →Vedavaag Systems Regulatory Approval
Vedavaag's WOS received IRDAI Certificate of Registration to act as Direct Life & General Insurance Broker. The group enters regulated insurance broking activity.
Hikal Regulatory Approval
Hikal's Bengaluru API facility received a Swissmedic GMP Certificate of Compliance. The certification supports wider access to European and other regulated markets.
Sun Pharmaceutical Industries Regulatory Approval
Sun Pharma gained US FDA approval for ILUMYA in adults with active psoriatic arthritis. The approval extends the drug's psoriasis use, with no financial value stated.
RNFI Services Regulatory Approval
RNFI received RBI no-objection to acquire control of Smart Payment Solutions Private Limited. Remaining tranches may proceed, but no transaction value is disclosed.
Shalby Regulatory Approval
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.
Elantas Beck India Regulatory Approval
Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.